Heron Therapeutics | HRTX - 贸易债权人

金融业

USD 0.38

USD 252.26M

现金及等价物

USD 20.72M

USD 11.12M

USD 229.85M

USD 92.15M

USD 149.65M

股息收益率

0

USD 38K

USD -3.88M

126

EPS每股收益

USD -0.02

股本和储备

USD 6.91M

USD 29.47M

债务利息支出

USD 600K

USD 433K

USD 140.64M

USD 58M

USD -2.95M

USD 40.55M

USD 38K

普通股股本

USD 188.31M

USD -2.95M

USD 40.59M

销售和管理费用

USD 23.74M

USD 54.57M

贸易债权人

USD 11.64M

应收帐款人

USD 89.59M

	贸易债权人	更改		日
ALKERMES	USD 142.86M		40.5M	2026-06
Alnylam Pharmaceuticals	USD 108.02M		18.61M	2026-06
Amarin	USD 18.8M		29.36M	2026-06
ANI Pharmaceuticals	USD 73.83M		4.14M	2026-06
Anika Therapeutics	USD 6.24M		103K	2026-06
Arrowhead Research	USD 27.78M		2.97M	2026-06
Eisai	JPY 87.53B		11.64B	2026-06
Emergent BioSolutions	USD 112.2M		500K	2023-12
GlaxoSmithKline	GBP 14.34B		7M	2026-06
Heron Therapeutics	USD 11.64M		2.67M	2026-06
Insmed	USD 74.55M		1.18M	2026-06
Ligand Pharmaceuticals	USD 9.4M		27.7M	2026-06
Merck	USD 3.83B		36M	2026-06
Nektar Therapeutics	USD 10.03M		744K	2026-03
Neurocrine Biosciences	USD 691.3M		145.8M	2026-03
Omeros	USD 8.84M		4.42M	2025-06
Pacira	USD 17.51M		3.5M	2026-06
Regeneron Pharmaceuticals	USD 1.16B		132.2M	2026-06
Roche Holding	CHF 5.54B		237M	2026-06
Sangamo BioSciences	USD 10.74M		7.46M	2025-06
Ultragenyx Pharmaceutical	USD 39M		3M	2026-06
Veracyte	USD 8.02M		1.12M	2026-06
Vertex Pharmaceuticals	USD 3.61B		135M	2026-06